Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

Group 1 - The company held its fifth board meeting on December 26, 2025, with all nine directors present, including one attending via telecommunication [2][3] - The board approved several resolutions, including the completion of fundraising projects and the permanent allocation of surplus funds to working capital, with unanimous support [3][4] - A short-term loan application of 50 million yuan from China Agricultural Bank was also approved, with two related directors abstaining from the vote [4][5] Group 2 - The board approved the adjustment of directors and senior management, which will require shareholder approval [7][8] - A proposal to convene the first extraordinary general meeting of shareholders in 2026 was also passed unanimously [10] - The meeting is scheduled for January 16, 2026, with provisions for both on-site and online voting [11][12]

Group 1 - The company, Panlong Pharmaceutical (002864), announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 16, 2026, at 14:00 [1]

Core Viewpoint - Panlong Pharmaceutical announced the approval of several proposals, including the conclusion of fundraising projects and the permanent allocation of surplus funds to supplement working capital [2] Group 1 - The third meeting of the fifth board of directors of Panlong Pharmaceutical was held [2] - The company approved the proposal regarding the conclusion of fundraising projects [2] - Surplus funds from the fundraising will be permanently allocated to enhance working capital [2]

Group 1 - The core point of the article is that Panlong Pharmaceutical announced the convening of its fifth board meeting to discuss adjustments to its board and senior management personnel [1] - The meeting will take place on December 26, 2025, in Xi'an, Shaanxi Province, combining both in-person and remote participation [1] - For the first half of 2025, Panlong Pharmaceutical's revenue composition shows that pharmaceutical manufacturing and sales accounted for 99.34%, while other segments contributed 0.52% and health products made up 0.14% [1] Group 2 - As of the report, Panlong Pharmaceutical has a market capitalization of 3.3 billion yuan [2]

南财智讯12月29日电，盘龙药业公告，公司于2025年12月26日召开第五届董事会第三次会议，审议通过 了《关于募投项目结项并将节余募集资金永久补充流动资金的议案》。同意"中药配方颗粒研发及产业 化项目"结项，该项目已达到预定可使用状态并转固，能够满足当前已备案品种的生产需求。截至2025 年11月30日，该项目建设投入8,695.38万元，节余募集资金5409.79万元（含利息及尚未支付的合同款， 实际金额以资金转出当日余额为准）。公司拟将上述节余募集资金永久补充流动资金，用于日常生产经 营。实施完毕后，项目尚未支付的合同款将由公司以自有资金支付，公司将办理募集资金专户销户手 续。 ...

中泰证券股份有限公司 关于陕西盘龙药业集团股份有限公司 募投项目结项并将节余募集资金永久补充流动资金的核查 意见 中泰证券股份有限公司（以下简称"中泰证券"、"保荐机构"）作为陕西盘龙 药业集团股份有限公司（以下简称"公司"或"盘龙药业"）向特定对象发行 A 股股 票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所股票 上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等相关法律和规范性文件的规定，对盘龙药业部分募投项目结项并将节 余募集资金永久补充流动资金的事项进行了审慎核查，具体情况如下： 一、募集资金及投资项目的基本情况 （一）本次向特定对象发行股票募集资金的基本情况 经中国证券监督管理委员会证监许可[2023]1709 号文核准，公司于 2023 年 9 月 19 日向特定对象发行人民币普通股（A 股）9,352,740 股，发行价格为每股 人民币 32.29 元，募集资金总额为人民币 301,999,974.60 元，已由中泰证券股份 有限公司于 2023 年 9 月 27 日汇 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-056 陕西盘龙药业集团股份有限公司 关于调整公司董事及高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日陕西盘龙药业集团股份有限公司（以下简称"公司"）董事兼董事会秘 书吴杰先生因个人身体原因申请辞去公司董事、董事会提名委员会委员及董事会 秘书职务。公司第五届董事会第三次会议审议通过了《关于调整公司董事及高级 管理人员的议案》，同意提名孟重先生为公司董事候选人，同意提名谢晓林先生 为董事会提名委员会委员，同意聘任赵庆波女士为公司董事会秘书。现将具体情 况公告如下： 一、关于公司董事及高级管理人员辞职的情况 公司董事会于近日收到吴杰先生递交的书面辞职报告，吴杰先生因个人身体 原因申请辞去董事、董事会提名委员会委员、董事会秘书职务。吴杰先生辞去上 述职务，后续仍在公司任职。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》及《公司章程》的有关规定，吴杰先生的董事会秘书辞职报告自送达董事 会时生效。截至本公告披露日，吴杰先生持有公司股票 675,00 ...

本次募投项目结项并将节余募集资金永久补充流动资金事项不构成关联交 易，亦不属于《上市公司重大资产重组管理办法》规定的重大资产重组。现将有 关情况公告如下： 一、本次向特定对象发行股票募集资金的基本情况 证券代码：002864 证券简称：盘龙药业 公告编号：2025-054 陕西盘龙药业集团股份有限公司 关于募投项目结项并将节余募集资金 永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"或"盘龙药业"）于 2025 年 12 月 26 日召开了第五届董事会第三次会议审议通过了《关于募投项目 结项并将节余募集资金永久补充流动资金的议案》。同意"中药配方颗粒研发及 产业化项目"结项并将节余募集资金 5,409.79 万元（含利息及尚未支付的合同款， 实际金额以资金转出当日余额为准）永久补充流动资金。上述节余募集资金永久 补充流动资金实施完毕后，项目尚未支付的合同款将在满足付款条件时由公司以 自有资金支付，公司将办理资金划转和募集资金账户销户手续。 根据《深圳证券交易所上市公司自律监管指引第 1 号— ...